Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $36.95.
Several research analysts recently commented on the stock. BidaskClub lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Bank of America Corporation boosted their price objective on shares of Ascendis Pharma A/S from $36.00 to $46.00 in a research note on Thursday, September 28th. Leerink Swann reiterated a “hold” rating and set a $28.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 23rd. Finally, Wells Fargo & Company reiterated a “buy” rating and set a $51.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd.
A number of institutional investors have recently modified their holdings of ASND. Janus Henderson Group PLC acquired a new position in Ascendis Pharma A/S during the 2nd quarter valued at approximately $15,403,000. EcoR1 Capital LLC increased its stake in Ascendis Pharma A/S by 44.5% during the 2nd quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock valued at $41,157,000 after purchasing an additional 456,900 shares in the last quarter. OppenheimerFunds Inc. acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at approximately $8,334,000. Marshall Wace North America L.P. acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at approximately $5,022,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at approximately $5,022,000. Institutional investors and hedge funds own 64.00% of the company’s stock.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.24). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.78 million. Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The company’s revenue was down 61.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.53) EPS.
ILLEGAL ACTIVITY WARNING: “Analysts Set Ascendis Pharma A/S (ASND) Price Target at $36.95” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2958149/analysts-set-ascendis-pharma-as-asnd-price-target-at-36-95.html.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.